HB4434, the Cosmetic Supply Chain Transparency Act of 2025, would amend the Federal Food, Drug, and Cosmetic Act to create a new federal framework for cosmetic supply chain transparency. The bill requires suppliers, manufacturers, and other entities in the cosmetic supply chain to provide brand owners with detailed ingredient, safety, testing, and manufacturing information upon request, including hazard data, safety data sheets, heavy metal testing results, fragrance allergen statements, and certificates of analysis. It also requires suppliers to test for certain nonfunctional constituents once they are added to an FDA-maintained list and to provide updated analytical results to brand owners before sale.
The bill directs the Secretary of Health and Human Services, through FDA, to create and maintain a list of nonfunctional constituents known or reasonably expected to be present in cosmetics and ingredients, with an initial proposed list, public comment period, advisory committee input, and annual updates. It also establishes a petition process for adding substances or new lists, and requires FDA guidance on analytical testing and detection limits. In addition, the bill expands FDA’s ability to request supply chain information when a cosmetic is suspected to be adulterated, misbranded, or otherwise in violation of federal law, and it authorizes civil penalties of up to $10,000 per day for violations of the new transparency and testing requirements.
A significant feature of the bill is its treatment of state authority. It expressly preserves state and local laws that prohibit or limit cosmetic ingredients, require ingredient reporting, or provide greater transparency, disclosure, or protection than the federal amendments. It also states that the Modernization of Cosmetics Regulation Act of 2022 should not be construed to preempt state action except as expressly provided, signaling a strong anti-preemption approach and allowing states to maintain or adopt stricter cosmetic safety rules.
The general sentiment reflected by the bill’s text and sponsorship is supportive of stronger consumer protection, supply chain accountability, and safer cosmetics. The bill is introduced by multiple House members and is framed around transparency and safety rather than deregulation. No committee transcript or vote record is available here, so there is no recorded floor or committee debate to indicate broader partisan sentiment or formal opposition.
The main points of contention likely concern compliance burden, trade secret and formulation confidentiality, and the scope of federal versus state regulation. Cosmetic manufacturers, suppliers, fragrance and flavor companies, and retailers may view the reporting, testing, recordkeeping, and petition requirements as costly or operationally complex, while consumer, public health, and environmental advocates are likely to support the added disclosure and testing. The bill’s explicit preservation of stronger state laws may also be a point of concern for industry groups that prefer uniform national standards.
The bill would amend Chapter VI of the Federal Food, Drug, and Cosmetic Act to add a new subchapter on cosmetic supply chain transparency, creating new federal duties for suppliers, manufacturers, and brand owners. It would require disclosure of ingredient and safety information, FDA rulemaking and list maintenance for nonfunctional constituents, testing and certification obligations, recordkeeping, and civil penalties for noncompliance. It also reinforces state authority by limiting federal preemption and preserving state ingredient restrictions and disclosure requirements that are more protective than federal law.
The bill’s overall tone is pro-consumer and pro-safety, with a clear emphasis on transparency, hazard identification, and stronger oversight of cosmetic ingredients and supply chains. Because no committee discussion or votes are provided, there is no direct evidence of opposition or bipartisan division in the available record. Based on the text alone, the measure appears designed to appeal to public health and consumer protection priorities.
Likely areas of contention include the cost and feasibility of supply chain testing, the administrative burden of maintaining records and responding to FDA requests, and the potential exposure of proprietary formulation information. Industry stakeholders such as cosmetic manufacturers, suppliers, fragrance and flavor companies, and retailers may object to the breadth of disclosure and testing requirements, while public health, environmental, and consumer advocates are likely to support them. Another likely dispute is the bill’s anti-preemption language, which preserves stronger state cosmetic laws and could create a patchwork of requirements across jurisdictions.